Tan et al. recently reported a new approach to neutralize IL-6; a non-signaling membrane-bound IL-6 receptor (mbaIL-6) composed of anti-IL-6 scFv and the hinge and transmembrane domain of CD8α.88 Co-expression of mbaIL-6 did not change the anti-tumor efficacy (Fig. 8A–D), in vivo expansion, IFN-γ production and the proportion of phenotypes (naïve, effector, central memory and effector memory) of human primary CAR-T cells. Here, IL6 is linked to neoplasm.